Context Therapeutics (CNTX) Expected to Announce Earnings on Thursday

Context Therapeutics (NASDAQ:CNTX) is projected to issue its quarterly earnings data before the market opens on Thursday, March 20th. Analysts expect the company to announce earnings of ($0.05) per share for the quarter.

Context Therapeutics Stock Performance

Context Therapeutics stock opened at $0.80 on Wednesday. Context Therapeutics has a 52 week low of $0.64 and a 52 week high of $2.75. The firm has a market capitalization of $59.62 million, a price-to-earnings ratio of -0.87 and a beta of 2.06. The company has a 50 day moving average price of $0.88 and a 200 day moving average price of $1.46.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the company. D. Boral Capital reaffirmed a “buy” rating and issued a $9.00 target price on shares of Context Therapeutics in a research report on Wednesday, January 15th. JMP Securities assumed coverage on Context Therapeutics in a research report on Wednesday, January 8th. They set an “outperform” rating and a $4.00 price objective for the company. Finally, Citizens Jmp raised Context Therapeutics to a “strong-buy” rating in a research note on Wednesday, January 8th. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Buy” and an average target price of $6.33.

About Context Therapeutics

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.